#8
AI Drug Discovery for GLP-1
The first AI-discovered obesity treatment entered Phase II trials in 2025, compressing a 12-year development cycle to under 3. This approach boasts a 90% clinical trial success rate, outperforming the industry average of 14% and promising affordable alternatives for the 650 million obese adults globally.
0
Photos (1)
Comments on "AI Drug Discovery for GLP-1"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.